Evidence of genetic susceptibility to immune-related dermatitis in patients with melanoma treated with immune checkpoint inhibitors.
Researchers identified genetic markers that may help predict which cancer patients are at higher risk for skin problems from immunotherapy, enabling better preparation.
Immune checkpoint inhibitor (ICI)-mediated dermatitis is a common treatment-related adverse event. The cohort-derived PRS showed modest discrimination for dermatitis risk (AUC 0.63).
What the study was
- Study design
- Cohort study
- Population
- patients
- Sample size
- 744
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Melanoma research
Why it surfaced
Score 8/10 [PROMISING_PRELIMINARY]: Cohort study (Journal Article) matched 'Novel therapeutics: immunotherapy, CAR-T'. Components — novelty:2/3, relevance:3/3, design:1/2, population:2/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.